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Available online xxxxObjective. To evaluate two non-imaging models designed to predict distant metastasis (stages IIIC–IV) in en-
dometrial carcinoma (EC). Both used preoperative histological and biological ﬁndings. One used primary tumoral
size, the other did not.
Methods. 374 patients operated on for EC by hysterectomy and at least bilateral pelvic lymphadenectomy
were included. Patient's characteristics, preoperative histological, biological ﬁndings and primary tumoral size
were used to calculate for each patient two scores (one for each model) for distant metastasis. The accuracy of
the models was evaluated in terms of areas under the receiver operating characteristic curves (AUCs), rates of
false negatives, and number of patients in the group at low risk to predict stages IIIC–IV.
Results. 309 and 65 patients had FIGO stages IA–IIIB and IIIC–IV respectively. Thrombocytosis and leukocytosis
were not signiﬁcantly different between patients who had distant metastasis and those who did not. CA125
serum level was signiﬁcantly higher in patients who had distant metastasis (71.2 vs 32.0 U/mL, p b 0.001). High-
risk preoperative histology and primary tumor diameter N 3 cm were more frequently observed in patients who
had distant metastasis (55.4% and 39.9%, p = 0.02 and 21.3% and 8.5%, p = 0.003). The AUC were 0.65 [0.63–
0.67] and 0.68 [0.63–0.67] with 54% and 93.4% sensitivity, 64% 19.1% speciﬁcity. Two hundred and twenty nine pa-
tients (61.2%) and 62 (17.0%) were classiﬁed as low risk; among them, 30 patients (13.2%) and 4 (6.4%) had ﬁnal
stage IIIC or IV.
Conclusion. Both models turned out to have a low discrimination power in our population. However, the score
using primary tumoral size permits to identify a subgroup of patients in whom metastatic probability is low and
lymphadenectomy unnecessary. Preoperative CA125 level, histological ﬁndings and primary tumoral size remain
prognostic factors of stages IIIC–IV and should be included in predictive models.
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In North America and Europe, endometrial cancer (EC) is the most
frequent cancer of the female genital tract and the fourthmost common
cancer site [1]. The main prognostic factors at diagnosis are: stage,
grade, histological subtype, myometrial depth invasion [2] and
lymphovascular space involvement (LVSI) [3]. Five year overall survival
is 83% for endometrioid carcinoma, 62% for clear cell carcinoma and 53%
for serous papillary carcinoma [2].imaging models for predicting distant metastasis in patients with
yno.2016.05.008
2 M. Koskas et al. / Gynecologic Oncology xxx (2016) xxx–xxxThe standard surgical treatment for stage I EC is total hysterectomy
with bilateral salpingo oophorectomywith or without lymphadenecto-
my. Systematic lymphadenectomy does not improve overall survival or
disease-free survival [4,5] and is not recommended in low risk EC, for
whom the prevalence of lymph node (LN) metastasis is 5% [6,7]. For
the high risk group (type 1 grade 3 stage I, stage II, or type 2 or in
presence of LVSI), lymphadenectomy is often recommended because
it has been suggested to improve overall survival [8,9]. Nonetheless,
preoperative histology cannot predict accurately ﬁnal histological type
and grade [10] and preoperative Magnetic Resonance Imaging (MRI)
[11] or PET-FDG [12] are less effective than lymphadenectomy to diag-
nose LN metastasis.
Considering the inability of a single tool to identify LN metastasis in
EC, statistical models combining preoperative characteristics have been
developed to accurately predict this risk. Recently, predictive models
based on preoperative criteria such as CA125 level andMRI [13] and his-
tological grade [14] have been described to identify a low risk group of
LN metastasis. A score based on preoperative volume index, serum
CA125 level and tumor grade/histology enabled to determine the risk
of LN metastasis encompassing the risk of para-aortic LN metastasis
with a good accuracy in patients with EC [15].
Luomaranta et al. developed a promising predictive model, combin-
ing preoperative biological factors (thrombocytosis, leukocytosis and
CA125 serum level) and histological factors to identify patients who
may not beneﬁt from lymphadenectomywith anAUC of 0.81 and a neg-
ative predictive value of 95.7% [16]. More recently, Tuomi et al. devel-
oped a similar risk scoring system including biological factors
(thrombocytosis and CA125 serum level), preoperative histology and
primary tumoral size [17]. To dispense with MRI for prediction of LN
and distant metastasis in EC could be cost effective and useful in institu-
tions without MRI accessibility. Several guidelines (including the
American College of Radiologists (ACR)) does not systematically recom-
mend preoperativeMRI for EC [18]. At the contrary, preoperative leuko-
cyte count, platelet count and CA125 serum level could be easily
accessible through blood sample analysis, which is systematically per-
formed before surgery as part of the preoperative anesthetic evaluation.
The aim of this study was to evaluate the scores described by
Luomaranta et al. [16] and Tuomi et al. [17] to predict LN and distant
metastasis against an independent external dataset.2. Material and methods
2.1. Study population
From January 1995 to December 2014, data on 435 patients with EC
from Gasthuisberg Hospital (Leuven, Belgium) were retrospectively re-
corded into a database by three different researchers (AV, JU and MK).
Patient's characteristics, preoperative tumoral and histological ﬁnd-
ings as well as ﬁnal tumoral characteristics were extracted from the re-
port of the patient ﬁle.
Only patients with presumed early stage EC (stages I/II) who
underwent at least pelvic lymphadenectomy were screened for inclu-
sion in the study. Patients who received neoadjuvant chemotherapy,
who had concomitant ovarian or cervical carcinoma, clinical stage IV
or recurrent diseases were excluded.
The decision to perform lymphadenectomy was based on preopera-
tive tumoral characteristics and avoided in low risk EC during the last
decade [4,5]. Consequently, most patients who had grade 1 or 2
endometrioid corpus cancer with greatest surface dimension ≤2 cm,
myometrial invasion ≤50%, and no intraoperative evidence of macro-
scopic disease were treated with hysterectomy only [19]. Pelvic and
para-aortic lymphadenectomy were performed as previously described
[20]. Pelvic lymphadenectomy comprised at least resection of the exter-
nal iliac and obturator LNs. Para-aortic lymphadenectomy included re-
section of all nodes from the precaval, laterocaval, interaortocaval,Please cite this article as: M. Koskas, et al., External validation of non-
endometrial cancer, Gynecol Oncol (2016), http://dx.doi.org/10.1016/j.ygpreaortic, and lateroaortic areas up to the renal veins. Based on these
criteria, we ﬁnally included 374 patients in this study.
2.2. Score establishment
Score calculation was based on methodologies previously described
[16,17]. Preoperative biological data (leukocyte count, platelet count
andCA125 serum level)were recorded anddivided in twogroups: leuko-
cytosis was deﬁned as a leukocyte count N8.2 × 109/L, thrombocytosis
was deﬁned as a platelet count N360 × 109/L and high CA125 serum
level was deﬁned as N35 U/mL. Preoperative histological ﬁndings obtain-
edwith either biopsy, curettage or polyp resection by hysteroscopywere
divided in two risk groups: high risk histology group encompassing grade
3 endometrioid carcinoma, carcinosarcoma, clear cell carcinoma and se-
rous carcinoma and low risk histology group encompassing grade 1 or
2 endometrioid carcinoma. Primary tumor diameter of 3 cm was chosen
as the cut-off value [17]. A score of 0 was attributed if leukocyte count
were b8.2 × 109/L or platelet count were b360 × 109/L or CA125 serum
level were b35 U/mL or for low risk histology group or for primary
tumor diameter b3 cm. A score of 1 was attributed in other cases.
Then, for the Luomaranta et al. model we applied the formula
previously described [16]: 2× leukocytosis + 3× thrombocytosis + 7×
× elevated CA125 + 4× high risk histology.
For the Tuomi et al. model we applied the formula previously de-
scribed [17]: 1× thrombocytosis + 3× elevated CA125 + 2× high risk
histology + 2× large tumor.
For eachmodel, we built the area under the receiver operating char-
acteristic (ROC) curve (AUC). Since the correspondence between the
score and LN or distant metastasis was not reported, it was not possible
to build calibration curve for the Luomarata et al. model. As described by
Luomarata et al., we used 6 as a cut-point to establish FN rate. For the
Tuomi et al. model, calibration curve was built and as described by the
authors, we used 1 as a cut-point to establish FN rate.
2.3. Evaluation of the models
2.3.1. Discrimination
Discrimination was quantiﬁed with the area under the receiver op-
erating characteristic (ROC) curve (AUC). The AUC reﬂects the ability
of a test to discriminate between a diseased and a non-diseased subject
across all possible levels of positivity. A 95% CI was calculated for each
AUC. AUC ranges from 0 to 1, with 1 indicating perfect concordance,
0.5 indicating no better concordance than chance, and 0 indicating per-
fect discordance.
2.3.2. FN rate
For prediction model, cutoff values reported by the scores of
Luomaranta et al. and Tuomi et al. were considered to deﬁne the sub-
group of patients with a low predicted probability of LN or distant me-
tastasis. For both scores, positive and negative predictions were
compared with observed issues.
2.3.3. Clinical utility
One of themain aims of models is to identify the largest subgroup of
patients with a low risk of LN or distant metastasis. For bothmodels, we
report the number of patients predicted as being negative or having a
low probability of distant metastasis.
The numeric variables were analysed using Student's t-test. A
p value b 0.05 was considered statistically signiﬁcant.
3. Results
Biological data including preoperative leukocyte count, platelet
count and CA125 serum level were not available for 61 patients. For
the remaining 374 patients, biological data were recorded. Delay be-
tween blood sample and surgery was b 30 days for all patients.imaging models for predicting distant metastasis in patients with
yno.2016.05.008
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Median (mean) 35.0 (71.2) 19.0 (32.0)
Range 4.0–420.0 3.0–327.0
CA125 b0.001
≤ 35 U/mL 33 50.7% 236 76.4%
N35 U/mL 32 49.3% 73 23.6%
Leukocytosis 0.07
Median (mean) 6.42 (6.92) 6.98 (7.39)
Range 3.87–12.71 2.44–13.81
Leukocytosis 0.32
≤8.2 × 109/L 50 77% 216 70%
N8.2 × 109/L 15 23% 93 30%
Thrombocytosis 0.08
Median (mean) 265.0 (263.8) 276.0 (281.5)
Range 127.0–609.0 82.0–562.0
Thrombocytosis 0.06
≤360 × 109/L 62 95,3% 265 85.7%
N360 × 109/L 3 4.7% 44 14.3%
Preoperative histology 0.22
Endometrioid carcinoma 43 66% 240 77.7%
1 20 49% 112 47%
2 9 21% 74 32%
3 15 30% 54 21%
Carcinosarcoma 5 7.8% 17 5.5%
Serous carcinoma 12 18.4% 35 11.3%
Clear cell carcinoma 5 7.8% 17 5.5%
Preoperative histology 0.02
Low risk 29 44.6% 186 60.1%
High risk 36 55.4% 123 39.9%
3M. Koskas et al. / Gynecologic Oncology xxx (2016) xxx–xxxThree hundred and nine patients (83%) had loco regional disease
(stages IA–IIIB) and 65 patients (17%) had distant metastasis (stages
IIIC–IV) including 60 patients with stage IIIC and 5 patients with stage
IV. Mean ages of the advanced disease group and non-advanced disease
groupwere respectively 67.5 and 65.8 years old (p= 0.21). Mean num-
ber of LNs harvestedwas signiﬁcantly higher in patients in patientswith
distant metastasis (29.0 vs 23.6, p = 0.008). Postoperative characteris-
tics of the two groups are presented in Table 1.
Preoperative biological and histological data in ﬁnal postoperative
groups are presented in Table 2. CA125 serum level was signiﬁcantly
higher in advanced disease group (p b 0.001). Preoperative histology
was more frequently high-risk histology in advanced disease group
(55% vs 40%, p = 0.03). When available (365/374 patients), primary
tumor diameter was more frequently N 3 cm in patients who had LN
or distant metastasis (21.3% and 8.5%, p = 0.003). However,
thrombocytosis and leukocytosis were not signiﬁcantly different be-
tween the two groups.
For CA125 level, FN rate was 12.3% (33/269). For leukocytosis, FN rate
was 18.8% (50/266). For thrombocytosis, FN rate was 19.0% (62/327). For
preoperative histology, FN rate was 13.5% (29/215). For primary tumoral
size (with a cut off value of 30 mm), FN rate was 8.5% (11/130).
The AUC for the Luomaranta score was 0.65 [0.63–0.67] (Fig. 1).
Using 6 as a cut-point, the sensitivity, speciﬁcity, positive and negative
predictive values were 53.8%, 64.4%, 24.1% and 86.8% respectively
(Table 3).
The AUC for the Tuomi scorewas 0.68 [0.66–0.70] (Fig. 1). Using 1 as
a cut-point, the sensitivity, speciﬁcity, positive and negative predictive
values were 93.4%, 19.1%, 18.8% and 93.6% respectively (Table 3).
Our primary analyses found a signiﬁcant difference between CA125
serum level, preoperative histology and primary tumoral size between
the advanced stage group and the non-advanced stage group whereas
no signiﬁcant difference was found between leukocytosis and
thrombocytosis. So, we hypothesized that only CA125 serum level, pre-
operative histology and primary tumoral size were predictive of distant
metastasis in presumed early stage EC and built a recursive partitioningTable 1











Age at diagnosis, y 0.21
Median (mean) 70.0 (67.5) 66.0 (65.8)
Range 31.0–83.0 19.0–72.0
Primary site tumor extension b0.001
≤50% 14 21% 181 59%
N50% 30 47% 91 29%
Cervical stroma 10 15% 25 8.2%
Serosa or adnexa 11 17% 11 3.5%
Vagina 0 0 1 0.3%
Size, mm 0.002
Median (mean) 40.0 (41.9) 34.0 (34.7)
Range 15.0–90.0 3.0–120.0
Size 0.003
b30 mm 11 17% 119 38.5%
≥30 mm 50 77% 185 59.9%
Unknown 4 6% 5 1.6%
Histology b0.001
Endometrioid carcinoma 35 54% 224 72.5%
1 13 37% 111 49.5%
2 7 20% 64 28.5%
3 15 43% 49 22%
Carcinosarcoma 6 9% 24 7.7%
Serous carcinoma 18 28% 43 14%
Clear cell carcinoma 6 9% 18 5.8%
Number of LN harvested 0.008
Median (mean) 28.0 (29.0) 21.0 (23.6)
Range 5.0–72.0 1.0–77.0
Please cite this article as: M. Koskas, et al., External validation of non-
endometrial cancer, Gynecol Oncol (2016), http://dx.doi.org/10.1016/j.ygmodel based on these three predictors. The recursive partitioning
model categorized the population into eight groups according to their
distantmetastasis probability (Fig. 2). CA125 levelwas the ﬁrst node per-
mitting to discriminate patients according to their metastatic probability.
Patients with low CA125 serum level/low risk histology and primary
tumor smaller than 30 mm (N= 62) had a prevalence of distant metas-
tasis of 6.4%. Patients with high CA125 serum level/high risk histology
and primary tumor larger than 30 mm (N = 40) had a prevalence of
LN or distant metastasis of 50.0%.
4. Discussion
The aim of the study was to evaluate a two models previously de-
signed to predict the risk of LN and distant metastasis (stages IIIC–IV)
in EC [16,17]. Both scores designed by turned out to have a low discrim-
ination power in our population to identify patients who may not ben-
eﬁt from lymphadenectomy for EC staging. A simple alternative based
on preoperative histological ﬁndings, CA125 serum level and primary
tumor size showed similar results.
Our study population was similar with the training cohorts. Mean
ageswere similarwith the Finnish study population and ethnical origins
are likely to be also similar since both populations were Caucasian. Dis-
tribution of histological subtypes was different than in training set pop-
ulations with a higher proportion of high-grade histological subtypes in
our validation set population. Sixty patients (17%) had positive LNs in
our population which was higher than described in previous studies
[21]. These ﬁndings are likely due to the fact that in our center,
lymphadenectomy was not performed in stage IA grade 1 or 2 and
tumor diameter ≤2 cm.
In our population, the Luomaranta score had a low discrimination
power (AUC 0.65), low sensitivity and speciﬁcity (54% and 64% respec-
tively), low positive predictive value (24%) and moderate negative pre-
dictive value (87%) for identiﬁcation of patients with advanced disease
(stages IIIC–IV) in comparison with another model [13] based onimaging models for predicting distant metastasis in patients with
yno.2016.05.008
Fig. 1.ROC curves for the Luomaranta et al. score (red) and Tuomi et al. (blue) score in the study population. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
4 M. Koskas et al. / Gynecologic Oncology xxx (2016) xxx–xxxpreoperative data such as CA125 level and threeMRI parameters (depth
of myometrial invasion, LN enlargement and extension beyond the
uterine corpus) which had an AUC of 0.85 and a false negative rate of
1.4% to identify a low-risk group of LN metastasis. The Tuomi et al.
score [17] turned out to have similar characteristics. However, we
must underline that using a cut off value of 1 (as suggested by the au-
thors), this score permits to identify a group of patients (62/365 pa-
tients) with a low metastatic probability (6.4%).
The model described by Luomaranta et al. included preoperative bio-
logical characteristics such as platelet count and leukocyte count. Indeed,
platelets could be correlated with metastatic disease by several mecha-
nisms. First, tumor cells secrete cytokines and growth factors that pro-
mote thrombocytosis in many types of cancer [22]. Also, platelets could
promote in vitro and/or in vivo (i) angiogenesis by secretion of cytokines
[23,24], (ii) adhesion of tumor cells through a selectin-GPIIb-dependent
mechanism [25] or (iii) the epithelial-mesenchymal transition (EMT) of
cancer cells [26]. In EC, thrombocytosis, deﬁned by platelet count
N400 × 109/L, was reported to be more frequently observed in advanced
stages (III–IV) in Afro-Caribbean population [27] and Norwegian popula-
tion [28]. Thrombocytosis has been reported to be associated with worseTable 3
Distribution of scores according to the ﬁnal stage.
Final stages IA–IIIB Final stages IIIC–IV Total
Luomaranta et al. score (0–16)
0–5 (negative) 199 (86.8%) 30 (13.2%) 229
6–16 (positive) 110 (75.9%) 35 (24.1%) 145
Total 309 65 374
Tuomi et al. score (0–8)
0–1 (negative) 58 (93.6%) 4 (6.4%) 62
2–8 (positive) 246 (81.2%) 57 (18.8%) 303
Total 304 61 365
Please cite this article as: M. Koskas, et al., External validation of non-
endometrial cancer, Gynecol Oncol (2016), http://dx.doi.org/10.1016/j.ygoverall and progression-free survivals in advanced stages (III–IV)
[27–30]. Also, thrombocytosis was associated with poor prognostics fac-
tors (stage, grade, LVSI and depth of myometrial invasion) [29].
Leukocytes secrete immunoglobulins that promotes cell migration
and therefore contribute to EC carcinogenesis [31]. Leukocytosis has
been associated with advanced stages of EC (III–IV) and worse overall
and progression-free survival in a Norwegian population [28]. An
American study found that leukocytosis was associated with higher
tumor size,more frequent stage III or IV, LVSI andworse overall survival
[32].
In our population, leukocytosis and thrombocytosis were not signif-
icantly different between advanced and non-advanced disease groups
contrarily to Luomaranta et al. and Tuomi et al. who found that leukocy-
tosis and thrombocytosis, deﬁned by reference values of Finnish adult
female population, were signiﬁcantly different.
CA125 serum levels in EC have been reported to be associated with
prognostic factors such as myometrial invasion, cervical involvement
or histological, grade [33], FIGO stage [33,34], LVSI [35], LN metastasis
[34], and progression-free survival or overall survival [33]. Nonetheless,
cut-off values varied from 20 [34] to 105 [36]. A recent retrospective
study found that cut-off values could varywith age: CA125 serum levels
superior to 35U/mLwere associatedwithworse cancer speciﬁc survival
within the patients aged 50 years old or more, whether CA125 serum
levels superior to 105 U/mL were associated worse cancer speciﬁc sur-
vival within the patients aged years old or younger [36]. Yamazawa
et al. showed that CA125 serum levels in EC were higher in serum
than the immunostaining in primitive tumoral tissue, suggesting that
CA125 was secreted by metastatic cells and would explain the correla-
tion between higher stage and worse prognosis [37]. Moreover, preop-
erative CA125 serum levels have proved to be more associated with LN
metastasis than inﬂammatory markers (neutrophil/lymphocyte ratio
and platelet/lymphocyte ratio) in a retrospective study of patients
with endometrioid EC [38].imaging models for predicting distant metastasis in patients with
yno.2016.05.008
Fig. 2.Recursive partitioningmodel predictingdistantmetastatic probability. Thismodel categorized thepopulation into eight groups according to their distantmetastatic rate (in bold and
italic).
5M. Koskas et al. / Gynecologic Oncology xxx (2016) xxx–xxxValues of high CA125 serum level, standardized as N35 U/mL [39],
and histological grade and type, standardized by the GOG study [21],
were parameters that could be applicable to a population worldwide
and represent strengths of Luomaranta model. In the Tuomi et al.
model, adding primary tumoral size permitted to increase discrimi-
nation of the prediction. However, leukocytosis and thrombocytosis
should not remain in an accurate model to predict LN or distant me-
tastasis risk. Interestingly, in Luomaranta et al. score, if leukocytosis
and/or thrombocytosis were present (1 point) and elevated Ca
125 and high-risk histology were absent (0 point), the total
score (2× leukocytosis + 3× thrombocytosis + 7× elevated
CA125 + 4× high risk histology) was below 6, the cut-off value
retained by the authors of the score.
Predictivemodels based on prognostic factors to assess the risk of LN
or distant metastasis in presumed early stage EC are increasing. The
model described by Luomaranta et al. [16] and Tuomi et al. [17] turned
out to have a low discrimination power in our validation cohort but
could be a good alternative in case of lack imaging. Nonetheless, preop-
erative CA125 serum level, preoperative histology and primary tumoral
size only should be included in predictive models in association with
other prognostic factors. Further researches on biological prognostic
factors and improvement in preoperative tumoral evaluation using bio-
markers are required to enhance the accuracy of predictive models to
identify EC patients with distant metastasis.
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